Aro Biotherapeutics to Present Clinical Update from its Pompe Disease Program at the 22nd Annual WORLDSymposium

Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer

Aro BioTx Announces IND for ABX1100 ph 1 study in LOPD patients

Aro Biotherapeutics Doses First Patient in Phase 1b Trial of ABX1100 in Late-Onset Pompe Disease (LOPD)

Aro Biotherapeutics Appoints Glenn Crater, M.D. as Chief Medical Officer

Aro Biotherapeutics Opens Enrollment of Phase 1b Trial of ABX1100 in Patients with Late-Onset Pompe Disease (LOPD)

Aro Biotherapeutics to Present Updates on ABX1100, a CD71 Centyrin – Gys1 siRNA Conjugate for the Treatment of Pompe Disease at the 20th Annual WORLD Symposium 2024 Meeting

Aro Biotherapeutics Secures $41.5M Series B Financing

Aro Biotherapeutics Announces Start of First in Human Study with ABX1100, a Novel First in Class Centyrin-siRNA Conjugate in Development for Pompe Disease

Aro Biotherapeutics Receives FDA Rare Pediatric Drug Designation for ABX1100 for the Treatment of Pompe Disease

Aro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe Disease

Aro Biotherapeutics to Present New Preclinical Data Highlighting the Potential of Centyrin-siRNA Conjugates for the Treatment of Pompe Disease

Aro Biotherapeutics to Highlight Therapeutic Potential of Centyrin Oligonucleotide Conjugates at Upcoming Industry Conferences

Aro Biotherapeutics Expands Leadership Team with Appointment of Sukumar Sakamuri, Ph.D. as Chief Technology Officer

Aro Biotherapeutics Appoints Mittie Doyle MD, FACR as Chief Medical Officer

Aro Biotherapeutics Expands Leadership Team and Plans Move to New Philadelphia Headquarters to Drive Next Phase of Growth

Aro Biotherapeutics Debuts Lead Centyrin Candidate at 2019 OTS Meeting

Aro Biotherapeutics Expands Leadership Team with Addition of Proven Scientific Executives

Aro Biotherapeutics Announces $88 Million Series A Financing to Advance Development of Centyrin-Targeted Genetic Medicines

Aro Biotherapeutics Appoints Biotechnology Executive Dr. Christopher Mirabelli to its Board of Directors and Nucleic Acid Therapeutics Expert Dr. Masad Damha to its Scientific Advisory Board

Aro Collaboration with Ionis Advances with Option Exercise

Aro Biotherapeutics Appoints Leading Cancer Biologist Dr. Martin McMahon and Protein Structure and Design Expert Dr. Ronald Swanson to its Scientific Advisory Board

Aro Biotherapeutics and Ionis Enter Licensing and Collaboration Agreement Focused on Cell-Specific Delivery of Antisense Oligonucleotides

Aro Biotherapeutics Names Seasoned Biopharma Industry Veteran Scott Greenberg as Vice President, Business Development and Alliance Management

Aro Biotherapeutics Debuts Lead Centyrin Candidate at 2019 OTS Meeting

Aro Biotherapeutics Appoints Anthony Tolcher, MD, to Scientific Advisory Board

Aro Biotherapeutics to Present Corporate Overview at BioCentury Future Leader’s In the Biotech Industry Conference

Aro Biotherapeutics to Present Data on Lead Program, ABX900, at AACR

Aro Biotherapeutics Raises $13 Million and Establishes Leadership Team to Develop Next Generation of Protein Therapeutics